phenazopyridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2120 94-78-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phenazopyridine
  • gastracid
  • phenazopyridine hydrochloride
  • phenazopyridine HCl
A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.
  • Molecular weight: 213.24
  • Formula: C11H11N5
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 89.65
  • ALOGS: -3.02
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 45.76 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 41 % Hosey CM, Chan R, Benet LZ
S (Water solubility) 0.03 mg/mL Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 60 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.316 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.356 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 42.462 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 32.509 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 5.680 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 21.630 % High 1
herg hERG pIC50 4.895 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 5.808 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 23.878 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 6.890 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHA2,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KIT,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 82
kinase-selectivity-class ACVR2A,ACVR2B,AURKA,AXL,CDK4,DYRK1B,EPHB4,ERBB2,GRK2,IKBKB,MAP2K3,MAP2K6,MAP3K7,MAPK12,MAPK7,MAPK8,SIK2,STK33,SYK,TEK,TTK 21
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.482 High 1
mh-clint Mouse hepatocyte intrinsic clearance 140.929 High 1
mppb Mouse plasma protein binding (% unbound) 10.030 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.270 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 10.190 % High 1
rh-clint Rat hepatocyte intrinsic clearance 82.794 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 65.110 % High 1
rppb Rat plasma protein binding (% unbound) 10.380 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 170.216 uM High 1

Approvals:

DateAgencyCompanyOrphan
June 26, 2001 FDA ABLE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sulphaemoglobinaemia 252.15 16.60 41 5455 492 90622459
Methaemoglobinaemia 243.62 16.60 55 5441 3960 90618991
Urinary tract infection 103.40 16.60 109 5387 305523 90317428
Anaemia Heinz body 52.27 16.60 6 5490 0 90622951
Cystitis 44.65 16.60 35 5461 66683 90556268
Drug hypersensitivity 42.01 16.60 89 5407 463520 90159431
Dysuria 36.13 16.60 25 5471 39376 90583575
Haemolytic anaemia 34.59 16.60 16 5480 11681 90611270
Nephrolithiasis 33.38 16.60 26 5470 49059 90573892
Emotional distress 30.68 16.60 22 5474 36640 90586311
Anticholinergic syndrome 27.09 16.60 9 5487 2734 90620217
Micturition urgency 26.03 16.60 13 5483 11220 90611731
Mydriasis 25.19 16.60 14 5482 14998 90607953
Urinary retention 23.53 16.60 19 5477 37725 90585226
Respiratory alkalosis 21.37 16.60 8 5488 3440 90619511
Product dose omission issue 20.79 16.60 51 5445 291636 90331315
Uterine perforation 18.27 16.60 9 5487 7545 90615406
Hypoxia 17.87 16.60 22 5474 72377 90550574

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Methaemoglobinaemia 98.94 25.99 25 1294 5749 42614267
Anticholinergic syndrome 54.07 25.99 12 1307 1577 42618439
Urinary tract infection 53.61 25.99 35 1284 99249 42520767
Nephrolithiasis 35.72 25.99 19 1300 36811 42583205
Mental status changes 28.06 25.99 17 1302 42098 42577918

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Methaemoglobinaemia 335.56 17.67 81 5701 9087 110574430
Sulphaemoglobinaemia 253.71 17.67 41 5741 554 110582963
Urinary tract infection 105.38 17.67 106 5676 326176 110257341
Anticholinergic syndrome 74.64 17.67 21 5761 4259 110579258
Nephrolithiasis 44.94 17.67 33 5749 66179 110517338
Cystitis 42.78 17.67 32 5750 66004 110517513
Anaemia Heinz body 42.58 17.67 6 5776 29 110583488
Haemolytic anaemia 42.18 17.67 21 5761 20899 110562618
Dysuria 38.59 17.67 29 5753 60202 110523315
Urinary retention 36.95 17.67 30 5752 69653 110513864
Mental status changes 28.72 17.67 27 5755 76095 110507422
Emotional distress 27.41 17.67 21 5761 44826 110538691
Drug hypersensitivity 23.35 17.67 64 5718 454026 110129491
Uterine perforation 20.39 17.67 9 5773 6831 110576686
Mydriasis 19.60 17.67 13 5769 22144 110561373
Micturition urgency 18.72 17.67 12 5770 19308 110564209
Respiratory alkalosis 18.60 17.67 8 5774 5713 110577804
Hypoxia 18.56 17.67 28 5754 129487 110454030

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BX06 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Other urologicals
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:36333 local anaesthetic
CHEBI has role CHEBI:50903 carcinogenic agent
CHEBI has role CHEBI:149553 anticoronaviral agent

Related Drugs by ATC class:

G04BX Other urologicals 10 drugs
acetohydroxamic aciddapoxetinedimethyl sulfoxidemagnesium hydroxidemethenaminepentosan polysulfatephenyl salicylatesalicylic acidsuccinimidetiopronin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dysuria indication 49650001
Urinary Tract Irritation indication
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Glaucoma contraindication 23986001 DOID:1686
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Glomerulonephritis contraindication 36171008 DOID:2921
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypovolemic shock contraindication 39419009
Third trimester pregnancy contraindication 41587001
Hyperactive behavior contraindication 44548000
Uremia contraindication 44730006 DOID:4676
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Hepatic failure contraindication 59927004
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Hiatal hernia contraindication 84089009 DOID:12642
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Liver function tests abnormal contraindication 166603001
Folic acid deficiency contraindication 190633005
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Sleep automatism contraindication 247962006
Benign prostatic hyperplasia contraindication 266569009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Severe dehydration contraindication 450316000
Acute exacerbation of asthma contraindication 708038006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.39 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel alpha subunit Ion channel BLOCKER CHEMBL CHEMBL
Sterile alpha and TIR motif-containing protein 1 Enzyme Ki 4.16 CHEMBL
Snake venom metalloproteinase Bap1 Enzyme IC50 4.27 CHEMBL
Replicase polyprotein 1ab Enzyme Kd 5.30 CHEMBL

External reference:

IDSource
4019884 VUID
N0000147969 NUI
D05450 KEGG_DRUG
136-40-3 SECONDARY_CAS_RN
4017768 VANDF
4019884 VANDF
C0031379 UMLSCUI
CHEBI:71416 CHEBI
CHEMBL1242 ChEMBL_ID
DB01438 DRUGBANK_ID
CHEMBL1201022 ChEMBL_ID
D010621 MESH_DESCRIPTOR_UI
4756 PUBCHEM_CID
7616 IUPHAR_LIGAND_ID
357 INN_ID
K2J09EMJ52 UNII
203197 RXNORM
2316 MMSL
5266 MMSL
5267 MMSL
d00337 MMSL
002866 NDDF
004869 NDDF
15785009 SNOMEDCT_US
370310006 SNOMEDCT_US
387119006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Walgreens Urinary Pain Relief Maximum Strength HUMAN OTC DRUG LABEL 1 0363-0113 TABLET 97.50 mg ORAL unapproved drug other 11 sections
Walgreens Urinary Pain Relief HUMAN OTC DRUG LABEL 1 0363-0773 TABLET 95 mg ORAL unapproved drug other 11 sections
Walgreens Urinary Pain Relief HUMAN OTC DRUG LABEL 1 0363-7775 TABLET 95 mg ORAL unapproved drug other 11 sections
Walgreens Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 0363-7776 TABLET 97.50 mg ORAL unapproved drug other 11 sections
Wallgreens Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 0363-8455 TABLET 99.50 mg ORAL unapproved drug other 11 sections
Phenazopyridine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-2070 TABLET 100 mg ORAL UNAPPROVED DRUG OTHER 11 sections
UristatUTI Relief PakUTI Relief Pak HUMAN OTC DRUG LABEL 1 0440-8065 TABLET 95 mg ORAL UNAPPROVED DRUG OTHER 14 sections
Rugby Phenazopyridine HCl Urinary Tract Analgesic HUMAN OTC DRUG LABEL 1 0536-1411 TABLET 95 mg ORAL unapproved drug other 12 sections
Phenazopyridine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-620 TABLET, FILM COATED 100 mg ORAL unapproved drug other 16 sections
Phenazopyridine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-621 TABLET, FILM COATED 200 mg ORAL unapproved drug other 16 sections
Phenazopyridine HCl HUMAN PRESCRIPTION DRUG LABEL 1 10544-055 TABLET 100 mg ORAL unapproved drug other 12 sections
Phenazopyridine HCl HUMAN PRESCRIPTION DRUG LABEL 1 10544-077 TABLET 200 mg ORAL unapproved drug other 12 sections
Phenazopyridine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-115 TABLET 100 mg ORAL unapproved drug other 11 sections
Phenazopyridine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-571 TABLET 200 mg ORAL unapproved drug other 11 sections
CVS Health Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-001 TABLET 95 mg ORAL unapproved drug other 11 sections
Preferred Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-210 TABLET 99.50 mg ORAL unapproved drug other 11 sections
Preferred Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-333 TABLET 97.50 mg ORAL unapproved drug other 11 sections
CVS Health Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-523 TABLET 97.50 mg ORAL unapproved drug other 11 sections
Preferred Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-551 TABLET 95 mg ORAL unapproved drug other 11 sections
Discount Drug Mart Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-552 TABLET 97.50 mg ORAL unapproved drug other 11 sections
Family Wellness Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-599 TABLET 97.50 mg ORAL unapproved drug other 11 sections
Vexia Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 10956-703 TABLET 99.50 mg ORAL unapproved drug other 11 sections
Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 11673-270 TABLET 99.50 mg ORAL unapproved drug other 11 sections
Rite Aid Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 11822-3111 TABLET 99.50 mg ORAL unapproved drug other 11 sections
Rite Aid Urinary Pain Relief HUMAN OTC DRUG LABEL 1 11822-8855 TABLET 95 mg ORAL unapproved drug other 11 sections
Phenazopyridine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 12634-189 TABLET 200 mg ORAL unapproved drug other 11 sections
Select Brand Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 15127-138 TABLET 97.50 mg ORAL unapproved drug other 11 sections
Signature Care Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 21130-523 TABLET 97.50 mg ORAL unapproved drug other 11 sections
Signature Care Maximum Strength Urinary Pain Relief HUMAN OTC DRUG LABEL 1 21130-792 TABLET 99.50 mg ORAL unapproved drug other 11 sections
Phenazopyridine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-301 TABLET 200 mg ORAL Unapproved drug other 11 sections